Diabetes/Weight Loss Drug Associated With Risk for Type of Optic Neuropathy

susan fitzgerald A m i d a n ever -g row i ng demand for weight loss drugs comes a new study that suggests that semaglutide, marketed as Ozempic and Wegovy, may increase the risk for a form of blindness.for semaglutide, but further study is required to assess causality," concluded the study, published online July 3 in

Authors

Susan Fitzgerald

Publication Details

Journal: Neurology Today
Published: 2024-08-15
DOI: https://doi.org/10.1097/01.nt.0001050484.50871.d5
Primary Topic: Retinal Diseases and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Diabetes/Weight Loss Drug Associated With Risk for Type of Optic Neuropathy

Susan Fitzgerald

Aug 15, 2024

Neurology Today

Retinal Diseases and Treatments

article

Diabetes/Weight Loss Drug Associated With Risk for Type of Optic Neuropathy

Susan Fitzgerald

August 15, 2024article en

Abstract

Neurology TodayVol. 24(16)

Good health and well-being

Openalex Percentile: Top 77%

Retinal Diseases and Treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Diabetes/Weight Loss Drug Associated With Risk for Type of Optic Neuropathy — Susan Fitzgerald · Neurology Today (2024) | TGRS Research Map | TGRS